These investigators further confirmed that talazoparib enhanced autophagic flux in the MCF-7 breast cancer cell line by using the lysosomal acidification and late-stage autophagy inhibitor, Bafilomycin A1, which showed LC3-II accumulation in a time dependent manner as compared to talazoparib alone; in addition, p62/SQSTM1 degradation observed with talazoparib was blocked in the presence of BafA1. Here, SQSTM1 is linked to breast carcinoma.